As posted on Cancer Therapy Advisor: Nov 18, 2018
By: Leah Lawrence
Use of MYD88 L265P and immunoglobulin heavy chain variable region (IGHV) analysis was a safe, reliable, and accurate technique to help identify transformation of Waldenström… Continue reading
Source: Targeted Oncology
Click here to download the pdf of the presentation.
The 5th International IWMF Doctor – Patient Summit was held in New York City from October 13-14.
The IWMF has generously provided videos of the sessions on their website.
To access the sessions, please CLICK HERE.
Patients with symptomatic Waldenström macroglobulinemia (WM) benefit from first-line treatment with ibrutinib, which Steven P. Treon, MD, PhD, Bing Center for Waldenström Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, and colleagues describe as being highly active and safe… Continue reading
A head-to-head, open-label, multicenter, phase 3 clinical trial comparing the efficacy and safety of zanubrutinib (BGB-3111) with ibrutinib in patients with Waldenström macroglobulinemia (WM) is underway (ClinicalTrials.org Identifier: NCT03053440).1 The study also seeks to evaluate the… Continue reading
This morning, August 27, 2018, the US Food and Drug Administration (FDA) approved ibrutinib (IMBRUVICA, AbbVie) in combination with rituximab (RITUXAN) for the treatment of Waldenström’s macroglobulinemia. This combination is the first and only chemotherapy-free treatment option for patients with… Continue reading
Zanubrutinib (BGB-3111), an investigational small molecule inhibitor of BTK, showed promising activity in patients with Waldenström macroglobulinemia (WM), according to updated results presented at the 2018 European Hematology Association Congress.
First author Judith Trotman, MBChB, FRACP, FRCPA, clinical professor of… Continue reading